PROF. EDGAR GEORGE ENGLEMAN, M.D
Medical Practice at Hillview Ave, Palo Alto, CA
License number
California G24766
Category
Medical Practice
Type
Blood Banking & Transfusion Medicine
Address
Address
3373 Hillview Ave, Palo Alto, CA 94304
Phone
(650) 723-7960
(650) 725-4470 (Fax)
(650) 725-4470 (Fax)
Professional information
Edgar George Engleman, Palo Alto CA
Specialties:
Internal Medicine, Pathology, Blood Banking & Transfusion Medicine
Work:
Stanford Blood Ctr
3373 Hillview Ave, Palo Alto, CA 94304 Stanford University
300 Pasteur Dr, Stanford, CA 94305
3373 Hillview Ave, Palo Alto, CA 94304 Stanford University
300 Pasteur Dr, Stanford, CA 94305
Education:
Columbia University (1971)
Dr. Edgar G Engleman, Palo Alto CA - MD (Doctor of Medicine)
Specialties:
Internal Medicine
Address:
Stanford Blood Center
3373 Hillview Ave, Palo Alto 94304
(650) 723-2597 (Phone)
3373 Hillview Ave, Palo Alto 94304
(650) 723-2597 (Phone)
Certifications:
Internal Medicine, 1974
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
Stanford Blood Center
3373 Hillview Ave, Palo Alto 94304
Stanford Hospital and Clinics
300 Pasteur Dr, Stanford 94305
3373 Hillview Ave, Palo Alto 94304
Stanford Hospital and Clinics
300 Pasteur Dr, Stanford 94305
Education:
Medical School
Columbia University / College of Physicians And Surgeons
Graduated: 1971
U Calif-Moffitt Hosps
U Calif Hosp
Columbia University / College of Physicians And Surgeons
Graduated: 1971
U Calif-Moffitt Hosps
U Calif Hosp
Edgar George Engleman, Palo Alto CA
Specialties:
Pathologist
Address:
3373 Hillview Ave, Palo Alto, CA 94304
Education:
Columbia University, College of Physicians and Surgeons - Doctor of Medicine
Board certifications:
American Board of Internal Medicine Certification in Internal Medicine
Reversing Intestinal Inflammation By Inhibiting Retinoic Acid Metabolism
US Patent:
2013013, May 23, 2013
Filed:
Aug 22, 2012
Appl. No.:
13/592180
Inventors:
Hwei Xian Leong - Palo Alto CA, US
Edgar G. Engleman - Palo Alto CA, US
Edgar G. Engleman - Palo Alto CA, US
International Classification:
A61K 31/428, A61K 31/4184
US Classification:
514367, 514394
Abstract:
An agent that increases local concentration of retinoic acid (RA) in the intestine through modifying enzymatic pathways involved in RA metabolism is administered in a dose effective to inhibit or reverse production of inflammatory mediators by intestinal dendritic cells and thereby reduce intestinal inflammation and tumor growth associated with intestinal inflammation.
Combination Therapy Of Gamma-Interferon And B-Cell Specific Antibodies
US Patent:
2005005, Mar 17, 2005
Filed:
Dec 8, 2003
Appl. No.:
10/730856
Inventors:
Edgar Engleman - Palo Alto CA, US
Assignee:
INTERMUNE, INC. - Brisbane CA
International Classification:
A61K039/395
US Classification:
424145100, 424141100
Abstract:
A combination therapy is provided of IFN-γ and therapeutic antibodies that recognize determinants on hyperproliferative B lineage cells. The targeted cells are contacted with these agents either locally or systematically, usually systematically. The subject methods provide a means for therapeutic treatment and investigation of hyperproliferative disorders.
Treatment Of Systemic Lupus Erythematosus With Dehydroepiandrosterone
US Patent:
5817650, Oct 6, 1998
Filed:
Apr 4, 1997
Appl. No.:
8/833338
Inventors:
James L. McGuire - late of Stanford CA
Linda R. McGuire - Westboro MA
Ronald F. Van Vollenhoven - Stanford CA
Edgar G. Engleman - Stanford CA
Linda R. McGuire - Westboro MA
Ronald F. Van Vollenhoven - Stanford CA
Edgar G. Engleman - Stanford CA
Assignee:
The Board of Trustees of the Leland Stanford Junior University - Stanford CA
International Classification:
A61K 3156
US Classification:
514170
Abstract:
Systemic lupus erythematosus (SLE) is treated with dehydroepiandrosterone or its metabolite, sulfate ester, by itself or in combination with other therapies. Substantial improvement in SLE patients is observed during the course of treatment.
Treatment Of Systemic Lupus Erythematosus With Dehydroepiandrosterone
US Patent:
5567696, Oct 22, 1996
Filed:
Jun 7, 1995
Appl. No.:
8/485353
Inventors:
James L. McGuire - Stanford CA
Ronald F. Van Vollenhoven - Stanford CA
Edgar G. Engleman - Stanford CA
Ronald F. Van Vollenhoven - Stanford CA
Edgar G. Engleman - Stanford CA
Assignee:
The Board of Trustees of the Leland Stanford Junior University - Stanford CA
International Classification:
A61K 3156
US Classification:
514170
Abstract:
Systemic lupus erythematosus (SLE) is treated with dehydroepiandrosterone or its metabolite, sulfate ester, by itself or in combination with other therapies. Substantial improvement in SLE patients is observed during the course of treatment.